HomeCompareTSUSF vs MRK

TSUSF vs MRK: Dividend Comparison 2026

TSUSF yields 5.95% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSUSF wins by $4475.02M in total portfolio value
10 years
TSUSF
TSUSF
● Live price
5.95%
Share price
$17.25
Annual div
$1.03
5Y div CAGR
93.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4475.05M
Annual income
$4,283,537,150.78
Full TSUSF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — TSUSF vs MRK

📍 TSUSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSUSFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSUSF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSUSF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSUSF
Annual income on $10K today (after 15% tax)
$505.59/yr
After 10yr DRIP, annual income (after tax)
$3,641,006,578.16/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, TSUSF beats the other by $3,641,005,770.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSUSF + MRK for your $10,000?

TSUSF: 50%MRK: 50%
100% MRK50/50100% TSUSF
Portfolio after 10yr
$2237.54M
Annual income
$2,141,769,050.54/yr
Blended yield
95.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TSUSF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
3.9
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSUSF buys
0
MRK buys
0
No recent congressional trades found for TSUSF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSUSFMRK
Forward yield5.95%3.25%
Annual dividend / share$1.03$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR93.6%8.2%
Portfolio after 10y$4475.05M$30.7K
Annual income after 10y$4,283,537,150.78$950.29
Total dividends collected$4461.50M$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: TSUSF vs MRK ($10,000, DRIP)

YearTSUSF PortfolioTSUSF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,852$1,151.56$11,192$351.54+$660.00TSUSF
2$15,151$2,469.34$12,524$392.70+$2.6KTSUSF
3$21,923$5,711.57$14,015$438.65+$7.9KTSUSF
4$38,411$14,953.46$15,682$489.96+$22.7KTSUSF
5$88,504$47,404.85$17,547$547.23+$71.0KTSUSF
6$292,331$197,631.78$19,632$611.16+$272.7KTSUSF
7$1,493,902$1,181,107.95$21,963$682.53+$1.47MTSUSF
8$12,519,366$10,920,890.48$24,571$762.18+$12.49MTSUSF
9$178,987,863$165,592,140.88$27,486$851.08+$178.96MTSUSF
10$4,475,054,164$4,283,537,150.78$30,745$950.29+$4475.02MTSUSF

TSUSF vs MRK: Complete Analysis 2026

TSUSFStock

Tsuruha Holdings Inc. operates drugstores in Japan. It sells pharmaceutical and cosmetic products. As of October 15, 2021, the company operated 2,448 stores in Japan and 22 stores in Thailand. The company was founded in 1929 and is headquartered in Sapporo, Japan.

Full TSUSF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this TSUSF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSUSF vs SCHDTSUSF vs JEPITSUSF vs OTSUSF vs KOTSUSF vs MAINTSUSF vs JNJTSUSF vs ABBVTSUSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.